Market Research Reports and Industry Reports

TAKEDA , Challenges Ahead for its New European Presiden

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • PURCHASE BY
    SECTION
Post Nycomed and Millenium acquisition, the new leadership of non-Japanese CEO/President Mr. Weber will transform Takeda in a truly global Japanese company in the coming years. It is however important to see how he fulfills the Japanese expectation from these acquisitions and fills the gap for Takeda due to the recent failure of its key late stage pipeline candidates (TAK-875, TAK-700 in chemo experienced Prostate Cancer). From its remaining late stage pipeline candidates (Table 2) Vedolizumab, Contrave (Naltoxone + buproprion, obesity) and MLN-9708 (Ph III, Ixazomib, Multiple Myeloma) are important to drive its growth. Of the recent small to mid-sized consolidation activities in 2013 (Table 1), deals done with Natrogen (New-York, Natura alpha, IBD), Resolve therapeutics, and Inviragen demonstrate Takedas focused approach for selective therapy areas (GI Speciality, Autoimmune, Vaccines), while its deal with Arbor for out licensing EDARBI US rights reveals its decreasing focus on primary care therapy area for global market.Vortioxetine (Brintellix) US launch for MDD Likely in Early 2014 Competitive Enough Against Genericized MDD Market, Edivoxetine failure a moderate Positive- while development of Brexpiprazole looks a close competitor!.........Vedolizumab (MLN0002, UR, US/EU, vedolizumab, 47 integrin inhibitor, Ulcerative colitis / Crohns disease) and MLN-9708 (PhIII, Multiple Myeloma) are the most promising late stage two key candidates: Vedolizumab approval in 2014 in UC/CD by mid 2014 is key to watch out for-MLN-9708/Velcade- Our View on Takedas Multiple Myeloma franchise-TAK-700 - Unable to demonstrate OS benefit in chemo experienced patients- What to expect in chemo nave pool and in earlier setting?- This 30 page detailed report on Takeda pharmaceuticals provide insightful analysis on its recent M & A activities and potential of late stage pipeline candidates based on their global competitive landscape
Table 1 : DEALS DONE BY TAKEDA IN 2013
- Table 2 : KEY LATE STAGE PIPELINE CANDIDATES- TAKEDA
- Table 3 : Vortioxetine - MAJOR DEPRESSIVE DISORDER - LATE STAGE PIPELINE
-Table 4 : MAJOR DEPRESSIVE DISORDER - EARLY STAGE PIPELINE
- Table 5 : VORTIOXETINE- MAJOR DEPRESSIVE DISORDER - DRUGS
DISCONTINUED IN THE RECENT PAST
- Table 6: Vortioxetine - MAJOR DEPRESSIVE DISORDER COMPETITIVE LANDSCAPE
-Table 7 : PIPELINE LEUKOCYTE TRAFFIC INHIBITOR (INTEGRIN INHIBITOR)
- Table 8 : COMPETITIVE LANDSCAPE
MLN 0002/VEDOLIZUMAB VS. MARKETED MAB IN ULCERATIVE COLITIS
- TAble 9 : Takeda Competitive Landscape
MLN 0002/VEDOLIZUMAB VS. MARKETED MAB IN CROHNS
DISEASE
- Table 10 : Takeda MLN 0002/Vedolizumab Clinical trial Programme
- Table 11 : MLN9708 - DATA COMPARISON - NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)
- Table 12 : DATA COMPARISON - RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)
- TAble 13 : COMPARISON OF CY17 INHIBITORS PIPELINE DRUGS ACTING ON
ANDROGEN SYNTHESIS
- Table 14: TAK-700 - KEY CANDIDATES OF ANTI ANDROGEN THERAPY IN PC
- Table 15: Key Milestones of Takeda

List Of Tables

Chart 1 Anti-Depressants WW Competitive Landscape
- chart 2 : MLN9708 -Trial design of TOURMALINE-MM1 RRMM
- chart 3 : REPORTED ADVERSE EVENTS IN CLINICAL TRIALS -MLN9708
-Chart 4: TAK-700 - DRUGS ACTING THROUGH ANDROGEN PATHWAY IN PC
-Chart 5: Nesina US Prescription trend

List Of Figures

Table 1 : DEALS DONE BY TAKEDA IN 2013
- Table 2 : KEY LATE STAGE PIPELINE CANDIDATES- TAKEDA
- Table 3 : Vortioxetine - MAJOR DEPRESSIVE DISORDER - LATE STAGE PIPELINE
-Table 4 : MAJOR DEPRESSIVE DISORDER - EARLY STAGE PIPELINE
- Table 5 : VORTIOXETINE- MAJOR DEPRESSIVE DISORDER - DRUGS
DISCONTINUED IN THE RECENT PAST
- Table 6: Vortioxetine - MAJOR DEPRESSIVE DISORDER COMPETITIVE LANDSCAPE
-Table 7 : PIPELINE LEUKOCYTE TRAFFIC INHIBITOR (INTEGRIN INHIBITOR)
- Table 8 : COMPETITIVE LANDSCAPE
MLN 0002/VEDOLIZUMAB VS. MARKETED MAB IN ULCERATIVE COLITIS
- TAble 9 : Takeda Competitive Landscape
MLN 0002/VEDOLIZUMAB VS. MARKETED MAB IN CROHNS
DISEASE
- Table 10 : Takeda MLN 0002/Vedolizumab Clinical trial Programme
- Table 11 : MLN9708 - DATA COMPARISON - NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)
- Table 12 : DATA COMPARISON - RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)
- TAble 13 : COMPARISON OF CY17 INHIBITORS PIPELINE DRUGS ACTING ON
ANDROGEN SYNTHESIS
- Table 14: TAK-700 - KEY CANDIDATES OF ANTI ANDROGEN THERAPY IN PC
- Table 15: Key Milestones of Takeda

Takeda Pharma AS in Consumer Health (Estonia)

Takeda Pharma AS aims to continue as the leading pharmaceuticals producer in Estonia, providing high-quality products and staying engaged in new product development and innovation across various OTC categories.Euromonitor International

USD 150View Report

Takeda Partnering Deals and Alliances 2010 to 2017

The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the worlds leading life sciences companies.On demand company reports are prepared

USD 1495View Report

Takeda Cambridge Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Takeda Cambridge Ltd (TCB), formerly Paradigm Therapeutics Limited, a subsidiary of Takeda Pharmaceutical Company Ltd, pharmaceutical company that develops novel compounds addressing in various therapeutics areas. The company specializes in

USD 250View Report

Big Data in the Automotive Industry: 2017 – 2030 – Opportunities, Challenges, Strategies & Forecasts

“Big Data” originally emerged as a term to describe datasets whose size is beyond the ability of traditional databases to capture, store, manage and analyze. However, the scope of the

USD 2500View Report

The Big Data Market: 2017 – 2030 – Opportunities, Challenges, Strategies, Industry Verticals and Forecasts

Big Data originally emerged as a term to describe datasets whose size is beyond the ability of traditional databases to capture, store, manage and analyze. However, the scope of the

USD 2500View Report

ProSe (Proximity Services) for LTE & 5G Networks: 2017 – 2030 – Opportunities, Challenges, Strategies & Forecasts

First introduced in Release 12 of the 3GPP specifications, ProSe (Proximity Services) is a D2D (Device-to-Device) technology that allows LTE devices to detect each other and to communicate directly. It

USD 2500View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
Country Code.
If you want to purchase particular section from this report then kindly contact us at contact@aarkstore.com.

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    $ 500
  • Site Licence    $ 1000
  • Enterprisewide Licence    $ 1500
$ 500

Reports Details

Published Date : Jan 2013
No. of Pages :24
Country :Global
Category :Healthcare
Publisher :MP Advisors
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube